BioScrip Inc Receives a Buy from Jefferies

By Carrie Williams

Jefferies analyst Brian Tanquilut reiterated a Buy rating on BioScrip Inc (NASDAQ: BIOS) yesterday and set a price target of $2.50. The company’s shares closed yesterday at $2.61.

According to TipRanks.com, Tanquilut is ranked 0 out of 5 stars with an average return of -8.6% and a 37.2% success rate. Tanquilut covers the Healthcare sector, focusing on stocks such as Five Star Quality Care, Quest Diagnostics Inc., and U.S. Physical Therapy.

BioScrip Inc has an analyst consensus of Hold.

Based on BioScrip Inc’s latest earnings report from June 30, the company posted quarterly revenue of $232.5M and quarterly net profit of -$8.23M. In comparison, last year the company earned revenue of $247.2M and had a net profit of -$16.78M.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BIOS in relation to earlier this year. Most recently, in June 2016, Carter Pate, a Director at BIOS bought 25,000 shares for a total of $62,250.

BioScrip, Inc. provides home infusion and home care management solutions. It partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. The firm offers post-acute solutions, infusion services, and respiratory care services and home medical equipment. The company was founded in 1996 and is headquartered in Denver, CO.